Caffeine Synergizes with Another Coffee Component to Increase Plasma GCSF: Linkage to Cognitive Benefits in Alzheimer's Mice
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Retrospective and prospective epidemiologic studies suggest that enhanced coffee/caffeine intake during aging reduces risk of Alzheimer's disease (AD). Underscoring this premise, our studies in AD transgenic mice show that long-term caffeine administration protects against cognitive impairment and reduces brain amyloid-β levels/deposition through suppression of both β- and γ-secretase. Because coffee contains many constituents in addition to caffeine that may provide cognitive benefits against AD, we examined effects of caffeinated and decaffeinated coffee on plasma cytokines, comparing their effects to caffeine alone. In both AβPPsw+PS1 transgenic mice and non-transgenic littermates, acute i.p. treatment with caffeinated coffee greatly and specifically increased plasma levels of granulocyte-colony stimulating factor (GCSF), IL-10, and IL-6. Neither caffeine solution alone (which provided high plasma caffeine levels) or decaffeinated coffee provided this effect, indicating that caffeine synergized with some as yet unidentified component of coffee to selectively elevate these three plasma cytokines. The increase in GCSF is particularly important because long-term treatment with coffee (but not decaffeinated coffee) enhanced working memory in a fashion that was associated only with increased plasma GCSF levels among all cytokines. Since we have previously reported that long-term GCSF treatment enhances cognitive performance in AD mice through three possible mechanisms (e.g., recruitment of microglia from bone marrow, synaptogenesis, and neurogenesis), the same mechanisms could be complimentary to caffeine's established ability to suppress Aβ production. We conclude that coffee may be the best source of caffeine to protect against AD because of a component in coffee that synergizes with caffeine to enhance plasma GCSF levels, resulting in multiple therapeutic actions against AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coffee and Health: A Review of Recent Human Research
Higdon, J. V., & Frei, B. (2006) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390500400009 · Cited by 1,090 · cited 2×
“For example, 90 coffee is high in dietary phenols such as chlorogenic 91 acid and caffeic acid that are antioxidants [12].”
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
Midlife Coffee and Tea Drinking and the Risk of Late-Life Dementia: A Population-Based CAIDE Study
Eskelinen, M. H., Ngandu, T., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0920 · Cited by 428
Kempf, K., Herder, C., Erlund, I., Kolb, H., Martin, S., Carstensen, M., Koenig, W., Sundvall, J., Bidel, S., Kuha, S., et al. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28548 · Cited by 364
Does caffeine intake enhance absolute levels of cognitive performance?
Jarvis, M. J. (1993) · Psychopharmacology · doi:10.1007/bf02246949 · Cited by 249
van Gelder, B. M., Buijsse, B., Tijhuis, M., Kalmijn, S., Giampaoli, S., Nissinen, A., & Kromhout, D. (2007) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602495 · Cited by 228
Coffee Consumption and Cognitive Function among Older Adults
Johnson-Kozlow, M. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf119 · Cited by 173
Hameleers, P. A. H. M., Van Boxtel, M. P. J., Hogervorst, E., Riedel, W. J., Houx, P. J., Buntinx, F., & Jolles, J. (2000) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.218 · Cited by 134
Boyd, T. D., Bennett, S. P., Mori, T., Governatori, N., Runfeldt, M., Norden, M., Padmanabhan, J., Neame, P., Wefes, I., Sanchez-Ramos, J., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091471 · Cited by 128
Self-citation
Cited by
The impact of coffee on health
Cano-Marquina, A., Tarín, J. J., & Cano, A. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.02.002 · Cited by 321
Neuroinflammation and neurogenesis in Alzheimer's disease and potential therapeutic approaches
Sung, P.-S., Lin, P.-Y., Liu, C.-H., Su, H.-C., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030701 · Cited by 193
“Curcumin [194], quercetin [195], and caffeine/coffee [196,197] were shown to have anti-inflammatory roles, and therefore potentially beneficial for both AHN and protection against AD [198].”
BackgroundCrude caffeine reduces memory impairment and amyloid β1–42 levels in an Alzheimer’s mouse model
Chu, Y.-F., Chang, W.-H., Black, R. M., Liu, J.-R., Sompol, P., Chen, Y., Wei, H., Zhao, Q., & Cheng, I. H. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2012.04.148 · Cited by 106
Coffee intake and decreased amyloid pathology in human brain
Kim, J. W., Byun, M. S., Yi, D., Lee, J. H., Jeon, S. Y., Jung, G., Lee, H. N., Sohn, B. K., Lee, J.-Y., Kim, Y. K., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0604-5 · Cited by 86
Driscoll, I., Shumaker, S. A., Snively, B. M., Margolis, K. L., Manson, J. E., Vitolins, M. Z., Rossom, R. C., & Espeland, M. A. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw078 · Cited by 55
“In vitro and preclinical studies underscore some mechanisms by which caffeine may exert protective effects against cognitive impairment and Alzheimer’s disease (AD) (2,5).”
Metadata
- Authors
- Cao, C., Wang, L., Lin, X., Mamcarz, M., Zhang, C., Bai, G., Nong, J., Sussman, S., & Arendash, G.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2011-07-01
- Volume
- 25
- Issue
- 2
- Pages
- 323-335
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2146548067
- Cited by
- 75
- References
- 9
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.